Found: 35
Select item for more details and to access through your institution.
Identification of microenvironment features associated with primary resistance to anti-PD-1/PD-L1 + antiangiogenesis in gastric cancer through spatial transcriptomics and plasma proteomics.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Modernizing adverse events analysis in oncology clinical trials using alternative approaches: rationale and design of the MOTIVATE trial.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 6, p. 1879, doi. 10.1007/s10637-020-00938-x
- By:
- Publication type:
- Article
Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 4, p. 693, doi. 10.1007/s10637-018-0688-4
- By:
- Publication type:
- Article
First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 4, p. 674, doi. 10.1007/s10637-018-0674-x
- By:
- Publication type:
- Article
Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 6, p. 1044, doi. 10.1007/s10637-018-0601-1
- By:
- Publication type:
- Article
Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 3, p. 1116, doi. 10.1007/s10637-011-9671-z
- By:
- Publication type:
- Article
Erratum to: Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials.
- Published in:
- 2012
- By:
- Publication type:
- Correction notice
Dysphonia induced by vascular endothelium growth factor/vascular endothelium growth factor receptor inhibitors.
- Published in:
- 2010
- By:
- Publication type:
- Report
Reversible cardiogenic shock following 5-Fluorouracil infusion.
- Published in:
- 2010
- By:
- Publication type:
- Report
Clinical Benefit for Patients with Non-Small Cell Lung Cancer Enrolled in Phase I Trials.
- Published in:
- Oncology Research & Treatment, 2013, v. 36, n. 6, p. 357, doi. 10.1159/000351257
- By:
- Publication type:
- Article
Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma.
- Published in:
- PLoS ONE, 2017, v. 12, n. 12, p. 1, doi. 10.1371/journal.pone.0189848
- By:
- Publication type:
- Article
Radiotherapy in the Era of Immunotherapy With a Focus on Non-Small-Cell Lung Cancer: Time to Revisit Ancient Dogmas?
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. N.PAG, doi. 10.3389/fonc.2021.662236
- By:
- Publication type:
- Article
Macrophage depletion induces edema through release of matrix-degrading proteases and proteoglycan deposition.
- Published in:
- Science Translational Medicine, 2021, v. 13, n. 598, p. 1, doi. 10.1126/scitranslmed.abd4550
- By:
- Publication type:
- Article
Early Trial Discontinuation in Toxicity-Driven, Dose-Escalating, Phase I Cancer Trials: Occurrence, Outcomes and Predictive Factors.
- Published in:
- Pharmaceutical Medicine, 2016, v. 30, n. 1, p. 49, doi. 10.1007/s40290-015-0120-8
- By:
- Publication type:
- Article
Do perfusion and diffusion MRI predict glioblastoma relapse sites following chemoradiation?
- Published in:
- Journal of Neuro-Oncology, 2016, v. 130, n. 1, p. 181, doi. 10.1007/s11060-016-2232-8
- By:
- Publication type:
- Article
A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumours.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Severe Onycholysis and Eyelash Trichomegaly Following Use of New Selective Pan-FGFR Inhibitors.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Sicca Syndrome Induced by Immune Checkpoint Inhibitor Therapy: Optimal Management Still Pending.
- Published in:
- Oncologist, 2020, v. 25, n. 2, p. e391, doi. 10.1634/theoncologist.2019-0467
- By:
- Publication type:
- Article
Continuous Infusion of Cilengitide Plus Chemoradiotherapy for Patients With Stage III Non-Small-cell Lung Cancer: A Phase I Study.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Phase 1 study of the immunotoxin LMB‐100 in patients with mesothelioma and other solid tumors expressing mesothelin.
- Published in:
- Cancer (0008543X), 2020, v. 126, n. 22, p. 4936, doi. 10.1002/cncr.33145
- By:
- Publication type:
- Article
A double-edged sword: unusual multiple severe infections with pralsetinib: a case report and literature review.
- Published in:
- Frontiers in Medicine, 2024, p. 1, doi. 10.3389/fmed.2024.1402902
- By:
- Publication type:
- Article
Distant antimetastatic effect of enterotropic colon cancer–derived α4β7<sup>+</sup>CD8<sup>+</sup> T cells.
- Published in:
- Science Immunology, 2023, v. 8, n. 84, p. 1, doi. 10.1126/sciimmunol.adg8841
- By:
- Publication type:
- Article
The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers.
- Published in:
- Science Translational Medicine, 2024, v. 16, n. 731, p. 1, doi. 10.1126/scitranslmed.add1834
- By:
- Publication type:
- Article
Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort.
- Published in:
- Cancers, 2023, v. 15, n. 13, p. 3441, doi. 10.3390/cancers15133441
- By:
- Publication type:
- Article
Circulating Exhausted PD-1 + CD39 + Helper CD4 T Cells Are Tumor-Antigen-Specific and Predict Response to PD-1/PD-L1 Axis Blockade.
- Published in:
- Cancers, 2022, v. 14, n. 15, p. 3679, doi. 10.3390/cancers14153679
- By:
- Publication type:
- Article
Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Improving patient selection for immuno-oncology phase 1 trials: External validation of six prognostic scores in a French Cancer Center.
- Published in:
- International Journal of Cancer, 2021, v. 148, n. 10, p. 2502, doi. 10.1002/ijc.33409
- By:
- Publication type:
- Article
Pemetrexed-Induced Pneumonitis: A Case Report.
- Published in:
- Clinical Lung Cancer, 2009, v. 10, n. 5, p. 364, doi. 10.3816/CLC.2009.n.050
- By:
- Publication type:
- Article
From presentation to paper: Gender disparities in oncological research.
- Published in:
- International Journal of Cancer, 2020, v. 146, n. 11, p. 3011, doi. 10.1002/ijc.32660
- By:
- Publication type:
- Article
Exploratory window‐of‐opportunity trial to investigate the tumor pharmacokinetics/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancer.
- Published in:
- CTS: Clinical & Translational Science, 2022, v. 15, n. 1, p. 55, doi. 10.1111/cts.13002
- By:
- Publication type:
- Article
The Activity of Crizotinib in Chemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcSé-Crizotinib Program.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial.
- Published in:
- Targeted Oncology, 2021, v. 16, n. 1, p. 47, doi. 10.1007/s11523-020-00767-1
- By:
- Publication type:
- Article